TY - JOUR
T1 - Rosacea Treatments
T2 - What's new and what's on the Horizon?
AU - Gallo, Rosella
AU - Drago, Francesco
AU - Paolino, Stefania
AU - Parodi, Aurora
PY - 2010
Y1 - 2010
N2 - Rosacea is a common, chronic, cutaneous disorder presenting with recurrent episodes of facial flushing, erythema, papules, pustules and telangiectasias. It is a multifactorial disease and its various clinical presentations probably represent the consequence of combined different triggers upon a specific background. Its management is largely based on long-established treatments empirically tailored to the specific presenting symptoms and no real breakthrough has occurred to date. However, recent insights into the still rather obscure pathophysiology of rosacea seem to open the way for etiologically oriented treatments. These may include, on the one side, the more effective application of traditional drugs, such as tetracyclines and metronidazole, to specifically selected patients or, on the other side, new therapeutic options, such as vitamin D receptor antagonists. It is to be remarked that the quality of most studies evaluating rosacea treatment is rather poor, mainly due to a lack of proper standardization. For a major breakthrough to occur in the management of rosacea, we need both a better understanding of its pathogenesis and the adherence of future clinical trials to clearly defined grading and inclusion criteria, which are crucial for investigators to correctly compare and interpret the results of their work.
AB - Rosacea is a common, chronic, cutaneous disorder presenting with recurrent episodes of facial flushing, erythema, papules, pustules and telangiectasias. It is a multifactorial disease and its various clinical presentations probably represent the consequence of combined different triggers upon a specific background. Its management is largely based on long-established treatments empirically tailored to the specific presenting symptoms and no real breakthrough has occurred to date. However, recent insights into the still rather obscure pathophysiology of rosacea seem to open the way for etiologically oriented treatments. These may include, on the one side, the more effective application of traditional drugs, such as tetracyclines and metronidazole, to specifically selected patients or, on the other side, new therapeutic options, such as vitamin D receptor antagonists. It is to be remarked that the quality of most studies evaluating rosacea treatment is rather poor, mainly due to a lack of proper standardization. For a major breakthrough to occur in the management of rosacea, we need both a better understanding of its pathogenesis and the adherence of future clinical trials to clearly defined grading and inclusion criteria, which are crucial for investigators to correctly compare and interpret the results of their work.
UR - http://www.scopus.com/inward/record.url?scp=77954809925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954809925&partnerID=8YFLogxK
U2 - 10.2165/11537020-000000000-00000
DO - 10.2165/11537020-000000000-00000
M3 - Article
C2 - 20642292
AN - SCOPUS:77954809925
VL - 11
SP - 299
EP - 303
JO - American Journal of Clinical Dermatology
JF - American Journal of Clinical Dermatology
SN - 1175-0561
IS - 5
ER -